U.S., Aug. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07142551) titled 'Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response' on Aug. 19.
Brief Summary: The objective of this study is to determine the safety and clinical effects of alternating pharmacologic (i.e. supraphysiologic) testosterone therapy with darolutamide in men with metastatic prostate cancer as first line hormonal therapy. Correlative studies will be conducted to assess the effect of alternating therapy on quality of life, gene expression and metabolic changes associated with alternating therapy.
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Metastatic Castration-resistant Prostate Cancer
I...